News

Applications are open for the MedTech Innovator Competition 2021 »

MedTech Innovator is the largest accelerator of medical devices in the world. We provide an unparalleled platform to support startups with the access, visibility, and network to bring their innovations to patients. Our alumni have raised over $2B in follow-on funding, brought 75 products to the market, and achieved 11 acquisitions. In its latest CipherBio report, Silicon Valley Bank recognized MTI as having the most active fundraising portfolio in 2020 of any accelerator.

Applications are open for the 2021 program. This is a highly selective and unique opportunity for startups and scale-ups to be showcased and gain access to healthcare stakeholders including investors, customers, and industry leaders such as Johnson & Johnson, Baxter, Olympus, W. L. Gore, Nipro, Edwards Lifesciences, Dexcom, Asahi Intecc, Fujikura, Jabil Healthcare, Maxim Integrated Products, and others. This year, up to $500,000 in non-dilutive prizes will be awarded.

Showcase at Leading Industry Conferences

Among other benefits, companies selected for the 2021 program will receive showcase presentation slots and one complimentary registration to the MedTech Innovator Summit and WSGR Medical Device Conference in June as well as The MedTech Conference powered by AdvaMed in September.

Prizes

Compete for up to $500,000 in non-dilutive cash prizes and in-kind awards

Who Should Apply?

All early to mid-stage medical device, diagnostic, or digital health companies are encouraged to apply. Preference for the Accelerator program will be given to companies that have not yet raised a Series B. All companies are eligible for the Showcase program.

Companies do not need to relocate to participate. MedTech Innovator does not charge or take equity for participation, and there is no application fee.

Apply Now

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin